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 2008 Wiley-LissABSTRACT: This work was to investigate the effects of particle size and paddle speed on
the particle diffuisonal layer thickness happ in a USP dissolution apparatus II. After the
determination of the powder dissolution rates of five size fractions of fenofibrate,
including <20, 20–32, 32–45, 63–75, and 90–106 mm, the present work shows that
the dependence of happ on particle size follows different functions in accordance with the





 23:31 (R2¼ 0.98) throughout the particle diameter, d, from 6.8 to
106 mm. In contrast, at 100 rpm a transitional particle radius, r, of 23.7 mm exists,
under which linear relationship happ¼ 1.59r (R2¼ 0.98) occurs, but above which happ
becomes a constant of 43.5 mm. Thus, happ changes not only with particle size, but also
with the hydrodynamics under standard USP configurations, which has been overlooked
in the past. Further, the effects of particle size and paddle speed on happ were combined
using dimensionless analysis. Within certain fluid velocity/particle regime, linear
correlation of happ/d with the square-root of Reynolds number ðd$=yÞ1=2, that is,
happ=d ¼ 1:5207  9:25  104ðd$=nÞ1=2 (R2¼ 0.9875), was observed.  2008 Wiley-Liss,
Inc. and the American Pharmacists Association J Pharm Sci 97:4815–4829, 2008Keywords: diffusion; diffusional layer thickness; dissolution; USP dissolution
apparatus; in vitro models; particle size; hydrodynamics; fluid velocity; dimensionless
number; gastrointestinal/mathematical models; bioequivalence; fenofibrateINTRODUCTION
The Biopharmaceutics Classification System
(BCS) categorizes drugs into four classes accord-
ing to their solubility and permeability.1 The BCS
II class of compounds exhibits high permeability
and low solubility relative to the administeredheng’s present address is AstraZeneca Phar-
lmington, DE 19850.
ce to: Gordon L. Amidon (Telephone: 734-764-
763-6423; E-mail: glamidon@umich.edu)
aceutical Sciences, Vol. 97, 4815–4829 (2008)
, Inc. and the American Pharmacists Association
JOURNAL OF PHARMdose. For a BCS II drug formulated into an
immediate release (IR) dosage form, the combina-
tion of high drug permeability and adequate GI
transit time will lead to a rate and extent of oral
absorption that is controlled by the in vivo process
of drug dissolution.1,2
Mechanistically, one of the fundamental issues
in modeling and understanding dissolution is to
determine the relationship between the diffu-
sional layer thickness (happ) and particle size
under a defined set of hydrodynamic conditions.
In the past, the Noyes–Whitney equation dM/
dt¼(D/h)A(CsCt) has been widely used toACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2008 4815
4816 SHENG ET AL.describe drug particle dissolution,3 where h is a
thin static liquid layer at the solid surface under
steady state conditions. For the past half century,
the Noyes–Whitney equation has served as the
theoretical basis for many classical dissolution
models that assumed various relationships
between the drug particle size and happ. For
example, happ was assumed to be a constant by
Hixson and Crowell,4 while Higuchi and Hie-
stand5–7 proposed that it was approximately equal
to the radius of the particle, and Niebergall et al.8
determined it to be equal to the square root of the
particle radius. All of these assumptions imply
that the correlation between happ and particle size
is applicable to all particle size ranges. In recent
years, this correlation has been advanced by
setting the existence of a transitional particle size,
above and below which happ behaves differently
depending on the magnitude of the drug particle
radius. For example, based on modeling the
dissolution of polydispersed powders, Hintz and
Johnson9 proposed the concept of a transitional
particle size. Specifically, 30 mm was the critical
particle radius. This model stipulates that h is a
constant of 30 mm for particles with radii larger
than 30 mm, while for particles less than 30 mm h
equals the particle radius. However, the transi-
tional value of 30 mm is based on a rotating disk
hydrodynamic system, uses a compressed tablet,
and powder size plays no role. This hypothesis
seemed to have correlated reasonably well with
their powder dissolution profiles and those in
several subsequent studies.10,11 Nevertheless,
direct evidence of the relationship between h
and various particle sizes r in a USP dissolution
apparatus II needs to be collected. Further, when
such an assumption is extrapolated to a nonro-
tating disk system, well-defined hydrodynamic
conditions merit careful considerations. Recently,
Nystrom and colleagues used a Coulter Counter to
directly measure particle size and concluded that
a critical diameter of 15 mm existed for griseo-
fulvin and oxazepam, below which the happ
decreased substantially with decreasing particle
size. The effect of particle size on happ became less
significant when particles diameters were above
15 mm.12 More recently, employing the same
particle size measuring technique, Figueiredo
et al. concluded that the critical particle size
should be 22 mm for ibuprofen, where the value of
h was linearly proportional to particle diameter
(kd) when the diameter was less than 22 mm but
was a constant (kdcri) when the particle diameter
was above 22 mm.13JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 20In previously reported studies, even though the
dependence of happ on particle size has been
mathematically described, its dependence on the
dissolution hydrodynamics has received very little
consideration. Therefore, a complete examination
of happ as a function of both particle size and
pharmaceutically relevant hydrodynamic factors
is theoretically and practically significant. In this
article, we employed Eq. (1) to do so
happ
d





where d is the drug particle diameter, n0 is the
linear velocity of fluid in cm/s, y is the kinematic
viscosity (cm2/s) of the fluid, a and b are
parameters that can be estimated through experi-












where k is the mass transfer rate (cm/s), and D is
the diffusion coefficient of the drug molecule (cm2/
s). As early as 1952, Eq. (2) was theoretically
derived and experimentally validated by Ranz
and Marshall to describe the rate of evaporation of
pure liquid drops and water drops containing
dissolved and suspended solids, such as in spray-
drying operations.14,15 In a subsequent article
published in the same year, Ranz16 extrapolated
his theory to mass transfer of single particles and
packed beads. In 1954, Garner and his colleagues
applied this theory to dissolution from a fixed solid
sphere in fluid flow.17 Specifically, they found that
the dissolution of benzoic acid in a stream of water
was correlated with another equation of similar
functional form to the Ranz–Marshall equation
(Eq. 2), kd/D¼ 44þ 0.48(dn0/y)1/2(y/D)1/3. In 1960,
Bird18 elaborated the Ranz–Marshall equation to
describe simultaneous heat and mass transfer of a
liquid or solid sphere under forced convection. In
1962, Harriott19 applied Eq. (2) for depicting mass
transfer of benzoic acid, boric acid, zinc and lead
sulfate particles suspended in agitated and baffled
tanks. More recently, Fogler et al. employed Eq.
(2) to study the dissolution of poly-dispersed
particles.20 Drug powders dissolved in a USP
dissolution apparatus II would encounter a
similar hydrodynamic environment to that inves-
tigated in Harriott and Fogler’s studies: that is,
mass transfer from solid spheres under forced
convection.08 DOI 10.1002/jps
PARTICLE DIFFUSIONAL LAYER THICKNESS IN USP DISSOLUTION APPARATUS II 4817In this article, fenofibrate was selected to serve
as a model BCS II drug. Selection of USP II
conditions is pharmaceutically relevant and of
particular importance from a regulatory perspec-
tive. Moreover, five size fractions were utilized in
the current study to further characterize and
understand the impact of particle size on happ. The
focus of this work is to: (1) determine the diffusion
layer thickness happ for a BCS II model drug,
fenofibrate, in a USP dissolution apparatus II; and
(2) illustrate the dependence of happ on particle
size and hydrodynamics using function form
happ/d¼aþ b(dn0/y)1/2.THEORETICAL SECTION
Calculation of Diffusional Layer Thickness happ
The diffusion layer thickness happ of drug particles
in a USP dissolution apparatus II can be
calculated based on their dissolution rates. At
dissolution time zero, the initial weight of a single
drug particle is M0 ¼ ð4p=3Þrr30;n. At any time t
afterwards, the particle weight is Mt ¼ ð4p=3Þrr3t;n,
where r0,n and rt,n are the volume particle radius at
time zero and t, respectively. M0 and Mt can be
brought together by the mass balance of the drug
particle, namely,




where N is the total number of particles, Ct is
the drug concentration at time t, and V is the
dissolution volume. In addition, the Noyes–
Whitney equation was originally derived in the
slab coordinate. When it is applied to a spherical











Eq. (4) can be simplified to the following:
 drt
dt








where r is the density of drug particles, Cs is the
drug solubility in the dissolution medium, and
happ is the apparent diffusion layer thickness.
Thus, with known parameters including Cs, Ct, r,
V, D, and N, the relationship between rt and t can
be established, the derivative of which is con-
nected to happ through Eq. (5).DOI 10.1002/jps JOURNAFor a system that is approximately spherical,
Eq. (4) is still valid. However, in the case of
nonspherical shape, the particle mass M should
be related to the particle volume radius rn, and the
particle surface area A should be related to the
particle surface radius rs. The volume radius rn
can be measured directly by Coulter Counter
method. The surface particle radius is calculated
using equation A ¼ 4pr2s , where the surface area A
is determined by BET methodology. Therefore,











Further, if the ratio of rs/rn is assumed to be

















ðCs  CtÞ (7)
The ratio between the surface radius and volume
radius, that is, rs/rn, is defined as the shape factor.
This ratio is a fundamental property related to
the particle dissolution rate in addition to drug
solubility and diffusivity that are the essential
factors dictating the diffusion and convection
within the solid–liquid interface. The dissolution
of an individual particle presumably proceeds
in an isometric manner at the initial stage of the
dissolution test. Therefore, the shape factor could
be assumed as a constant in calculating the happ
values. Assuming each size fraction is monodis-
persed, we employed Eqs. (3) and (7) to calculate
happ. During early dissolution the change of
particle radius and consequently that of happ
are minimal. Therefore, generally the initial five
dissolution data points were used for the deter-
mination of average happ values.Dependence of happ on Particle Size and
Fluid Velocity
The diffusion layer thickness happ for drug
particles in a particular geometry is a function
of drug properties including particle diameter d
and diffusivity D, and fluid properties of fluid
velocity n0 and kinematic viscosity y23
happ ¼ f ðd;D; n0; yÞ (8)
Therefore we have n¼ 5 variables for happ of drug
particle dissolution in a USP vessel. These n¼ 5L OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2008
4818 SHENG ET AL.variables are built up from k¼ 2 independent
dimensions that are: length L (cm) and time T (s).
According to the p-theorem, the variables n¼ 5
can be reduced to three independent dimension-
less numbers, which are defined as happ/d,
Reynolds number Re¼dn0/y and Schmidt number
ScQ2¼ y/D. Then, Eq. (8) can be expressed as
happ
d
¼ f ðRe;ScÞ (9)
Most previous works, both theoretical and
practical,14–17,19,20,24 suggested the form of:
happ
d
¼ a þ b  ðReÞ1=2ðScÞ1=3 (10)
In this study, the kinematic viscosity of dissolu-
tion medium y and drug diffusivity of fenofibrate
D are constant, thus Eq. (1) arrives
happ
d





where a and b are constants and can be
determined using regression analysis of the
experimental data such as happ and d.EXPERIMENTAL
Materials and Preparation
Fenofibrate (>99% purity), sodium lauryl sulfate
and all other chemicals were of analytical grade
and were purchased from Sigma Chemical Com-
pany (St. Louis, MO). Distilled, deionized and
filtered water was prepared in house and used for
all experiments. Fenofibrate ‘‘as received’’ from
Sigma had a broad size distribution, with which
four size fractions, that is, 20–32, 32–45, 63–75,
and 90–106 mm were obtained by sieving. In brief,
the bulk material was initially dry sieved through
the USA standard test sieves (Newark Wire Cloth
Company, Clifton, NJ). Then, 300 mg of the dry
sieved fractions were well suspended into 60 mL of
0.9% NaCl solution containing 0.05% SLS, and
the suspensions were wet sieved through the
same standard sieves. The wet sieved fractions on
the sieve were rinsed with 0.9% NaCl solution
containing 0.05% SLS and subsequently with
water, and then they were dried overnight in a
vacuum oven at 308C. The <20 mm size fraction
was achieved by jet-milling the bulk material as
received from Sigma. About 100 g of fenofibrate
bulk material was jet-milled through a lab
scale size fluid energy grinder (Sturtevant Inc.,JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 20Hanover, MA) that was operated using com-
pressed nitrogen, with an approximate yield of
95%. The milling air setting was 60–70 PSIG, and
the feed air pressure was operated between 90 and
100 PSIG. The crystal form of the jet-milled
fenofibrate was also characterized using powder
X-ray diffraction (PXRD) and differential scan-
ning calorimetry (DSC) to confirm the absence of
amorphous material and process induced changes
in crystal form. All the five fractions of particles
were fully characterized with regards to their
specific surface area, particle volume diameter,
number diameter, and density. The USP pH 6.8
50 mM phosphate buffer without pancreatin was
prepared following standard procedures.25 Piece-
wise regression analysis and parameter estima-
tions were performed using Sigmaplot 10.0 (SPSS
Inc., Chicago, IL). Two segment linear piecewise
regression was applied to the particle radii r and
the corresponding happ, at each paddle speed.Powder X-Ray Diffraction (PXRD)
Powder diffraction patterns of jet-milled and ‘‘as
received’’ fenofibrate were recorded with a Scintag
X-ray diffractometer (Franklin, MA) using Cu Ka
radiation (l¼ 1.54 Å), tube voltage of 40 kV, and
tube current of 20 mA. The intensities were
measured at 2u values from 58 to 408 at a
continuous scan rate of 58/min.Differential Scanning Calorimetry (DSC)
The thermal behavior of jet-milled and ‘‘as
received’’ fenofibrate were studied using a TA
Instruments 2920 modulated DSC (TA Instru-
ments, New Castle, DE) with refrigerated cooling
system (RCS) in standard mode. Approximately
5–10 mg samples were weighed into aluminum
DSC pans, crimped, equilibrated to 808C and
then heated up to 1008C at a rate of 5.08C/min,
with nitrogen purge at 110 mL/min.Particle Size Determination
The mean volume particle size diameters for all
size fractions were determined using the Coulter
Counter (nonlaser light scattering) method. The
jet-milled material was first suspended in the
0.9% NaCl solution containing 0.25% SLS, satu-
rated with fenofibrate. Then the suspension was
quickly transferred into the 0.9% NaCl solution08 DOI 10.1002/jps
PARTICLE DIFFUSIONAL LAYER THICKNESS IN USP DISSOLUTION APPARATUS II 4819containing 0.1% SLS and saturated with fenofi-
brate, which served as the suspending medium
and testing electrolyte for all samples during
particle size measurement. It should be empha-
sized that the diameter given by the Coulter is a
volume equivalent diameter, namely, dn¼ (6n/p)1/3,
where n is the particle volume directly measured
by the Coulter.Specific Surface Area Measurement
The specific surface area of fenofibrate powders
was determined at liquid nitrogen temperature
using BET methodology employing nitrogen as
the adsorbate. The surface area was used to
calculate the particle surface radius by equation
A ¼ 4pr2s .
26
Solubility Measurement
The aqueous solubility of fenofibrate was mea-
sured at 378C in 0.25% SLS pH 6.8 phosphate
buffer, instead of water. Since SLS has a CMC of
0.25% (w/v) in water, it serves as a reasonable
surrogate of the in vivo surfactant properties
provided by bile salts and provides the necessary
enhancement in solubility and dissolution rate for
fenofibrate that is practically insoluble in water
with a solubility of <0.3 mg/mL. Fenofibrate
solubility was determined by suspending excess
fenofibrate powder in 5 mL buffer in a screw-
capped vial. The suspension was equilibrated by
shaking in an orbital shaker water bath (LAB-
LINE Instruments, Inc., Melrose Park, IL). At
suitable time intervals, 1.0 mL of aliquots were
drawn and filtered through 0.45-mm membrane,
and then diluted with an appropriate amount of
phosphate buffer prior to the spectrophotometric
assay at l¼ 292 nm using a UV spectrophot-
ometer (Beckman Coulter DU 650, Fullerton, CA).
The equilibrium solubility of fenofibrate was
established when the difference between three
consecutive measurements is within 1%, a process
that may take up to 7 days.Dissolution Profiles in USP Dissolution Apparatus II
The dissolution profiles of various size fractions of
fenofibrate were measured in a USP dissolution
apparatus II at 378C using pH 6.8 phosphate
buffer containing 0.25% SLS. For the jet-milled
fenobibrate, 50 mg powder was weighed into a
1.0 mL of eppendorf tube, then 0.5 mL of the
dissolution medium were added, and then theDOI 10.1002/jps JOURNAsuspension was sonicated at low power for 5 s. The
well dispersed jet-milled suspension was then
immediately transferred into the prepared dis-
solution vessel, and rinsed with the dissolution
medium three times of 5 mL each. The four bigger
size fractions of fenofibrate powders (50 mg) were
directly dropped into the 378C 500 mL dissolution
medium that was previously degassed. Dissolu-
tion experiments were conducted in triplicate at
both 50 and 100 rpm for each particle size. Aliquots
were drawn at 0.33–1 min intervals, filtered through
0.45-mm membrane and diluted if necessary prior to
UV spectroscopic analysis at l¼ 292 nm (Beckman-
Coulter DU 650, Fullerton, CA).RESULTS
Characterization of Fenofibrate Particles
As evident from the DSC traces of the jet-milled
and ‘‘as received’’ fenofibrate (Fig. 1a and b), a
negligible glass transition occurs around 458C
with a very small enthalpy of 0.0051 W/g,
followed by the melting point around 79.58C with
an enthalpy of fusion of approximate 95 J/g. This
DSC result indicates that no significant changes
in crystal forms or amorphous content were
introduced through the jet-milling process. These
results are further confirmed by PXRD (Fig. 2)
where the slightly decreased peak intensities are
consistent with a reduction in particle size.
The volume particle size distribution of each
size fraction is shown in Figure 3, and the surface
area equivalent particle radius, shape factor and
density for each size fraction are summarized in
Table 1. Visual observation via SEM shows the
irregular and multi-sided morphology of fenofi-
brate particles (Fig. 4), suggesting that fenofibrate
particles would dissolve in a relatively isometric
manner.
The diffusivity of fenofibrate was calculated as
7.4 106 cm2/s using the ADMET PredictorTM
1.2.1 (Simulation Plus Co., Lancaster, CA), which
used the Hayduk-Laurie formula D ¼ 13:26
105=h1:4waterV
0:589.27 This value is consistent with
the literature reported experimental value of
7.15 106 cm2/s using the rotating disk
method.28Dissolution Profiles of Fenofibrate
The solubility of fenofibrate was determined to be
150.4 1.4 mg/mL in 0.25% SLS 50 mM pH 6.8L OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2008
Figure 1. DSC thermogram of fenofibrate particles. a) Jet-milled fenofibrate particles
of <20 mm diameter; b) Fenofibrate sample ‘as received’ from Sigma Chemical Company.
Thermal scans obtained using 5–10 mg samples in crimped aluminum pans over a
temperature range of 808C to 1008C at a scan rate of 58C/min.
4820 SHENG ET AL.phosphate buffer. The dissolution profiles of
fenofibrate particles at 50 and 100 rpm are shown
in Figure 5. Several elements can be drawn from
these dissolution profiles. First, as expected, the
dissolution rates increase with decreasing particle
sizes in the following order: jet-milled material
(<20 mm)> 20–32> 32–45> 63–75> 90–106 mm
size fractions. This observation is consistent with
the larger surface area per unit weight of the
smaller particles. Secondly, the dissolution rates
of the jet-milled material are similar at the 50 and
100 rpm. Finally, the four larger size fractions of
fenofibrate dissolve faster at a paddle speed of
100 rpm than at 50 rpm, presumably due to the
higher fluid velocities at 100 rpm that lead toJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 20thinning of happ and subsequently more efficient
mass transfer.Dependence of Diffusional Layer Thickness on
Hydrodynamics and Particle Sizes
The dependence of happ on particle size and
hydrodynamics/fluid velocity were examined
and illustrated in the two following ways. The
first approach is bifunctional analysis demon-
strating happ as a function of r under different
paddle speeds, as shown in Figure 6. This
approach determined the transitional particle
size through which the value of happ exhibits a08 DOI 10.1002/jps
Figure 2. Overlay of powder X-ray diffraction pat-
terns of jet-milled fenofibrate particles of <20 mm dia-
meter and fenofibrate sample ‘as received’ from Sigma
Chemical Company. Intensities were measured using
Cu Ka radiation at 2u values from 58 to 408 at a scan rate
of 58/min.
PARTICLE DIFFUSIONAL LAYER THICKNESS IN USP DISSOLUTION APPARATUS II 4821different correlation with particle radius. Deter-
mination of transitional particle size has been
employed previously in the literature.9,12,13 The
second approach is dimensionless analysis using
Eq. (1), investigating the combined effects of
particle sizes and paddle speeds on happ.
Bifunctional analysis: The transitional particle
size for fenofibrate in a USP dissolution apparatus
II is fluid velocity dependant. Using piecewise
regression, the transitional particle sizes are deter-
mined by the goodness of fitting using square root
of overall correlation coefficient (R2), and the
values are 37.7 5.4 mm (R2¼ 0.9972) and 23.7Figure 3. Semi-logarithmic plot of cumulative
volume fraction of jet-milled and sieved fenofibrate
particles as a function of particle diameter determined
using a Coulter Counter.
DOI 10.1002/jps JOURNA0.6 mm (R2¼ 0.9998), under 50 and 100 rpm,
respectively (Fig. 6). For drug particles smaller
than the transitional sizes, the happ displays a
linear relationship with the drug particle radius.
The linear slopes vary with paddle speeds, and
the values are 1.71 (R2¼ 0.9872) and 1.59
(R2¼ 0.9828), at 50 and 100 rpm, respectively.
In comparison, for drug particles larger than the
transitional sizes, at 100 rpm a constant happ was
observed with an approximate value of 43.5mm for
any particles with radius larger than 23.7mm; and
at 50 rpm the happ value continues to increase
with particle size but at a slower rate. The





, as shown in Figure 7. Evidently, at










0.9769, throughout the tested particle size range
6.8–106 mm in this work. Whether this linear
relationship applies to particles in near-micron or
submicron range needs further research, partially
due to the complex microfluid dynamics surround-
ing these very small particles. In comparison, at
100 rpm the linear relationship transforms into





was then further exploited in dimen-
sional analysis.
Dimensionless analysis: According to Eq. (1)
happ/d¼aþ b(dn0/y)1/2, the Re number (dn0/y) was
calculated using drug particle diameter d (cm),
linear fluid velocity n0 (cm/s), and kinematic
viscosity y of dissolution medium (0.758
102 cm2/s) at 378C.29 The linear velocity of
fluid/dissolution medium in an agitated USP
vessel depends on the rotational speeds of paddle
and the location in the vessel. In addition, the use
of the linear velocity of the fluid is not convenient
in practice, and the rotational speed of the paddle
$ is readily available and can be easily adjusted to
the linear velocity through paddle diameter, that
is, n0 ¼ $ paddle diameter. It therefore lends to
the calculation of the Reynolds number using $,
that is, d$=y. The relationship between happ/d
and d$=y is proposed in Eq. (11):
happ
d




where Re is calculated based on the following: d is
the particle diameter in mm, $ is the rotational
speed of paddle in rpm, y is the kinematic viscosity
of dissolution medium in cm2/s, and the diameter
of the paddle is well defined according to USP.
Figure 8 demonstrates that the happ of suspendedL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2008
























<20 mm (jet-milled) 1.2 0.5 2.7 0.5 3.4 0.9 1.575 0.058 0.36 0.03 0.79
20–32 mm 13.8 6.2 16.2 5.2 16.1 0.6 0.296 0.031 0.64 0.02 1.01
32–45 mm 19.7 4.8 28.4 3.0 26.3 1.2 0.181 0.002 0.76 0.01 1.09
63–75 mm 34.4 4.4 44.6 11.2 37.1 1.0 0.154 0.001 0.76 0.02 1.25
90–106 mm 51.1 18.9 56.3 14.5 53.0 0.5 0.083 0.006 0.77 0.02 1.06
aNumber radius was measured using scanning electronic microscopy (SEM).
bSurface radius was converted through the surface area that was measured by BET methodology.
cVolume radius was directly measured using Coulter Counter method.
dShape factor was defined as the ratio of the surface equivalent radius to the volume equivalent radius, that is, rs/rn.
4822 SHENG ET AL.drug particles in the USP vessel can be success-
fully described with the semitheoretical equation
(Eq. 11). Here, happ/d exhibits a two-regional
dependence on particle Re, that is, ðd$=yÞ1=2. One
region is linear, where the particle Re is 	592,
and is described by happ=d ¼ 1:5207  9:25
104ðd$=yÞ1=2. Assuming the drug diffusivity is
7.15 106 cm2/s,28 this regression corresponds
to an R2¼ 0.9875 (p< 0.0001), and estimates the
values of a¼ 1.5207 0.0417 and b¼9.25
104 4.66 105. The other region describes
the relation for particles with smaller Re number
(either smaller particle size and/or slower paddle
speeds), the relationship between happ/d and Re
may be more complex.
DISCUSSION
Calculation of Diffusion Layer Thickness happ
Due to its mathematical simplicity, a spherical
shape is the best contour to select to experimen-Figure 4. Typical Scanning Electron Micrograph of
fenofibrate particles (63–75 mm).
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 20tally determine the value of happ, an approach that
was elaborated by Wang and Flanagan.21,22
Numerous attempts to prepare spherical and
crystalline fenofibrate particles for this study
were unsuccessful because fenofibrate either
formed amorphous spheres or crystalline needles
following recrystallization processes as confirmed
by polarized microscopy. Therefore, irregular
shapes of fenofibrate particles were employed
here with consideration given to their shape
factor; that is, the ratio of particle surface radius
to volume radius. Here, it is assumed that drug
particles would dissolve in an approximately
isotropic manner, implying that the shape factor
would remain unchanged. This assumption has
been used widely in the past when the shape
factors were considered constant, in the initial
stages of the dissolution testing. Even in the
case of dissolving crystals with a high degree ofFigure 5. Dissolution profiles of jet-milled and sieved
fenofibrate fractions in a USP Dissolution Apparatus II
at 50 rpm and 100 rpm. Dissolved fraction is shown as a
function of time. Data expressed as meanSD, n¼ 3.
08 DOI 10.1002/jps
Figure 6. Bifunctional analysis of the dependence of
particle boundary layer thickness, happ (mm), deter-
mined in a USP Dissolution Apparatus II at 50 rpm
and 100 rpm, on particle surface radius. Data expressed
as meanSD, n¼ 3.
Figure 8. Dimensionless analysis of the dependence
of diffusional layer thickness happ on particle sizes and
hydrodynamics in a USP Dissolution Apparatus II.
Data expressed as meanSD, n¼ 3.
PARTICLE DIFFUSIONAL LAYER THICKNESS IN USP DISSOLUTION APPARATUS II 4823nonisometricity sharp edges such as needles and
plates, the shape factor has been reported to
change insignificantly until considerable dissolu-
tion occurs.30,31 In addition to the shape factor, the
quantity of amorphous content, may also con-
tribute to nonisometric dissolution. PXRD and
DSC results confirmed the absence of detectable
amorphous form for the jet-milled material.
The thickness of a hydrodynamic boundary
layer is often defined as the distance from
the surface of the solid to the point where the
tangential velocity attains a value of 90% of the
main stream.23 In general, this layer thickness is
not easily evaluated from experimental work
except under well-defined hydrodynamic condi-
tions as in the case of the rotating-disk.23 In this
work, the happ is calculated using Eq. (7) toFigure 7. Plots of particle boundary layer
thickness, happ (mm), determined in a USP Dissolution
Apparatus II at 50 rpm and 100 rpm, as a function of
square root of particle surface radius. Data expressed as
meanSD, n¼ 3.
DOI 10.1002/jps JOURNAdescribe the distance over which the diffusion
process dominates the mass transfer. As such, it
reveals the drug dissolution in terms of how
resistance to mass transfer may occur in the solid–
liquid interface in a simple model. In addition, the
diffusional thickness can often be used to predict
changes in mass transfer caused by factors such as
chemical reactions.32,33 It is important to note
that the happ determined in a USP dissolution
apparatus is an apparent averaged value from all
particles. This averaged value is contributed from
the following two factors. One factor is the specific
hydrodynamic conditions, where the local envir-
onment of fluid dynamics surrounding each
individual drug particle is not the same through-
out the USP dissolution apparatus II vessel.34–38
The other factor is the monodispersion of the five
size fractions is not perfect, even though they are
all very narrowly distributed (Fig. 3).
Dependence of happ on Hydrodynamics and
Particle Sizes
Bifunctional Analysis with Transitional Particle Sizes
Dissolution phenomena have been studied in a
quantitative manner for more than a century,
during which various relationships between happ
and particle size have been proposed.5,8,9,12,13
Bifunctional analysis of fenofibrate dissolution
data suggests that Higuchi–Hiestand’s assump-
tion5,6 and Hintz–Johnson’s hypothesis9 appear to
be valid, whereas careful considerations should be
given to the powder dissolution occurring under
specific hydrodynamic conditions.
Higuchi–Hiestand assumed that happ was equal
to or greater than the particle radius, and conducted
their experiments with 2.2 mg of micronized
methylprednisolone (
25 mm) in 100 mL of waterL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2008
Table 2. Comparison of the Relationship between happ and r in: Higuchi–Hiestand’s Work, Hintz–Johnson’s Work
and the Current Work in a USP Dissolution Apparatus II
Conditions
Below




Value of Cr (mm)
Above
Cr: happ as a
Function of r
Higuchi–Hiestand1,2 happ is comparable to, or greater than the particle radius r
Hintz–Johnson3 happ¼ r (r< 30 mm) 30 Constant, 30 mm
USP dissolution apparatus II,
at 100 rpm
happ¼ 1.59r (r< 23.7 mm) 23.7 Constant, approximate 43.5 mm
USP dissolution apparatus II,
at 50 rpm
happ¼ 1.71r (r< 37.7 mm) 37.7 happ increases with r slowly
4824 SHENG ET AL.in bottles that were rotated at 6 rpm at 258C.5–7
In comparison with their work (Tab. 2), the current
study experimentally demonstrates that in a USP
dissolution apparatus II happ may be equal to or
greater than particle radius r, only if the specific
hydrodynamic conditions are provided. The first
observation is based on the data that at paddle
speed of 100 rpm, the particle radius r of 44.6
0.4 mm is not significantly different from the corre-
sponding happ value of 43.5 11.2 mm. The second
point was observed at both paddle speeds. For
example, at 50 rpm happ equals to 1.71r, and the
value of happ decreases to 1.59r at a higher paddle
speed of 100 rpm, both suggesting that happ could
be greater than particle radius.
The description of happ as a function of particle
size under both paddle speeds was compared with
Hintz’s work as well, as shown in Table 2. Both
sets of data consistently demonstrate the exis-
tence of a transitional particle size Cr in the 30 mm
size range, and a linear relationship between happTable 3. Particle Sizes and Re: Comparison of Fenofibrate
and Previous Studies Using the Function Form of Eq. (2)
System
USP dissolution apparatus IIa
Mass transfer from single particles and packed beds4–6
Mass transferb from a fixed solid sphere in fluid flow7
Mass transferc of solid particles suspended in agitated tank
Estimated the k value of polydisperse solid particles9
Mass transfer of a single particle in creeping-flow10
aThe unit for rotational speed $ is rpm, for particle size d is cm
bOverall mass transfer for the fixed sphere.
cThe fluid velocity was estimated using slip velocity presented i
dk is the mass transfer coefficient and equals to D/happ.
eThe experimental value is within 30% of the theoretical predict
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 20and r when particle size is below Cr. When particle
size is above Cr, a constant happ value, however,
was observed at 100 rpm. Further, despite the
similar observations, it is evident that distinct
differences exist between the Hintz–Johnson’s
assumption and our work in the following specific
aspects: (1) the value of Cr; (2) the linear slope
value between the happ and r; and (3) the value of
constant happ. These differences are attributed to
the differences in hydrodynamic conditions under
which the dissolution studies are conducted. In a
rotating disk system, a planar constant surface
area pertains rather than a powder dissolution of
spherical geometry where more complex hydro-
dynamics pertains. For example, based on
Levich’s equation h ¼ 1:61ðD=yÞ1=3ðy=$Þ1=2,23 a
diffusivity of fenofibrate as 7.15 106 cm2/s and
kinematic viscosity of the dissolution medium
as 7.58 103 cm2/s at 378C, for fenofibrate, a
rotational speed of 21 rpm would give a h equals
to 30 mm. Clearly, even though this assumptionPowder Dissolution in a USP Dissolution Apparatus II
Particle
Diameter
Range (mm) Reynolds Numbers of Fluids
2–106 0<Re< 5.8 104
600–1100 1<Re< 7 105
1270 20<Re< 103
s8 15–600 325<Re< 1.08 105
Not defined Not defined in the article
Not defined The correlation is verye good as of:
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Johnson study, the dissolution hydrodynamics in
these two systems are very different.
Dimensionless Analysis
The key dissolution variables employed in Eq. (1),
particle size and Reynolds number as an indicator
of the fluid dynamics, were compared to the
previous utilization of the Ranz–Marshall equa-
tion (Eq. 2). As shown in Table 3, the similarities
and differences are discussed as follows. In Ranz’s
original work on mass transfer of single particles
and packed beds,16 the theory was applied to
particle sizes in the range of 0.06–1.1 cm and Re
number ranging from 2 to as high as 105. In
later studies, the particle size varied from 15 to
1270 mm, and the Re number ranged from 1 to 105
(Tab. 3). Comparably, the Re number under
standard USP dissolution conditions such as
50 and 100 rpm is within the Re range tested
in the original Ranz theory14–16 and other
work.17,19,20,24,39 The Re number in a USP
dissolution apparatus II encompass a consider-
able range from a value of zero at the vessel wall to
the highest value at the paddle tip. Using equation
Re ¼ $d2$=y, the maximum Re numbers can be
determined as 2.9 104 and 5.8 104 at 50 and
100 rpm, respectively,35 where $ is the rotational
speed of the paddle, d$ is the diameter of the
paddle, and n is the kinematic viscosity of the
fluid. Although the mean particle size in this
work, 32–106 mm, is generally smaller than that
utilized by Ranz’s and others, our results have
shown that the theoretical diffusion layer thick-
ness happ/d¼aþ b(dn0/y)1/2 could be extrapolated
with remarkable accuracy to the particle size
range beyond the Ranz’s.
Industrial Significance of happ
Dependence of happ on Paddle Speeds and Particle
Size. Dimensionless analysis demonstrated a
bipartite behavior of the dependence of happ on
paddle speeds and particle size, which may be
contributed by several factors. First, crystal
defects and roughness on the particle surface
represent a larger percentage of the crystal weight
after milling, since the surface area to volume
ratio is increased. These effects were observed to
have a significant impact on dissolution rate for
particles with diameters in the micron range.
Second, at small particle sizes, turbulence in
the form of microeddies begins to play a more
important role in the hydrodynamics near to theDOI 10.1002/jps JOURNAdissolving surface, in other words a microenvir-
onment different from the bulk hydrodynamics is
created.40–42 It is also thought that the effective
eddy diffusivity of drug molecule in the turbulent
fluid may be very different from that in bulk
fluid.43 Surface roughness, crystal defects and
microeddies would lead to a faster dissolution
rate than expected using surface area and the
bulk fluid velocity. Further, jet-milling process
generally produces small particles with radius
of less than 10 mm, which is not perfectly
monodispersed even though it is considered
narrowly distributed compared with particles
larger than 20 mm. Subsequently, any nonperfect
monodisperse nature may contribute to the
derivation of an accurate estimation of happ.
Employing the assumption of monodispersity for
the jet-milled material may be an over-simplifica-
tion, particularly if the dissolution investigation is
primarily focused on particles less than 10 mm.
However, even with the consideration of poly-
disperse nature (e.g., 1% particle with radius of
0.7, 0.8, and 1.05mm, 7% of 1.3mm, 6% of 6mm, 4%
of 7 mm and 1% of 9.5 mm), the happ value varies
very little. The most plausible reason is that small
particles contribute to negligible amount of over-
all weight fraction and the subsequent dissolution
rate. Nevertheless, this region of small Re number
merits further research.
Eq. (11), happ=d ¼ a þ bðd$=yÞ1=2, was also
applied to in vitro dissolution behavior of other
drugs including digoxin and oxazepam indepen-
dently reported by Nystrom et al.12,44 In their
studies, dissolution rates were measured with two
different particle sizes under three rotational
speeds, that is, 350, 500, and 800 rpm. Dissolution








Rsq ¼ 0:9403 ðp ¼ 0:0052Þ








Rsq ¼ 0:9472 ðp ¼ 0:0063Þ
The successful fitting of digoxin and oxazepam
dissolution data into the function form of Eq. (11)
further supports the linear correlation between
happ/d and ðd$=yÞ1=2 and its use to estimate happL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2008
4826 SHENG ET AL.values for drug particles in the standard USP
dissolution II apparatus, based on the measured
particle size d and the rotational paddle speed $.happ for Poorly Soluble Drugs
Recent estimates suggest that the percentage of
BCS II drugs in the top US 200 oral IR products is
greater than 25%.45 Probably as a result of the
widespread application of combinatorial chemis-
try and high-throughout screening activities
during the drug discovery process,46,47 this per-
centage will probably increase. To ensure satisfac-
tory oral absorption, particle size reduction has
been widely used to increase the surface to volume
ratio and thus improve the dissolution rate of
poorly soluble drugs. The current work clearly
reveals that the happ values generally decrease
with decreasing particle size (Fig. 6). Therefore,
an increase in the dissolution rate resulting from a
particle size reduction process is attributed not
only to an increase in the surface area to volume
ratio, but also to a decrease in happ, an important
contribution that is rarely addressed in the
literature.
In addition, since the layer thickness happ
depends on the drug diffusivity D, the correspond-
ing happ for two drug substances with different D
values would be expected to be different. However,
it is likely that the happ would only change slightly
because: (1) according to the Levich theory,23 happ
is only dependent to the one-third power on D,
that is, h ¼ 1:61ðD=yÞ1=3ðy=$Þ1=2 and (2) drug
diffusivity of most small drug molecules is low and
in the range of 106–105 cm2/s.
Furthermore, the results in this article suggest
the following: (1) for drug particles with radius in
the range of 3.4–23.7 mm, happ is approximately 1.5-
fold of particle radius (Fig. 6), (2) under the paddle
speed of 50 rpm, the diffusional happ exhibits a linear
relationship with the square root of particle diameter,
across the studied particle size range (Fig. 7).
Finally, Figure 6 suggests that for small drug
particles, happ is not significantly different under
50 and 100 rpm. The exact size range for the small
particles, where happ is independent of paddle
speeds in a USP dissolution apparatus II, is yet
to be determined. In this work, the jet-milled
fenofibrate with a mean rn of 3.4 mm, demonstrates
that its happ is independent of fluid velocity. In the case
of cilostazol, the size limit could be in the low micron
range, that is, 13 mm. Cilostazol is a poorly soluble
compound with a water solubility of 6.25 mg/mL atJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 11, NOVEMBER 2037-C. Three size fractions with mean particle sizes of
13, 2.4, and 0.22 mm were prepared using techniques
hammer-mill, jet-mill and spray-drying, respectively.
In vitro powder dissolution profiles of 5 mg of these
cilostazol samples, in 900 mL of water, FaSSIF and
FeSSIF at 37-C in USP apparatus II, were equivalent
at the paddle speeds of 50 and 200 rpm.11 This result
indicates that the happ is independent of paddle speeds
when the cilostazol particles are smaller than 13 mm.
Both results suggest that the hydrodynamic consid-
erations are important for large particles, and very
small particles in micron range are less influenced by
hydrodynamics.Relevance to In Vivo Conditions
The unique result, namely, happ is independent of
fluid velocity for the very small particles, suggests
that the highly variable GI fluid velocity varying
with GI motility phases may not impact on the
happ of low micron range particles in in vivo. The
micronized powder of felodipine, with a median
particle size of 8 mm, may be an example of such a
drug. Felodipine is a poorly soluble, neutral and
lipophilic drug, and its oral absorption that is
indicated by AUC does not appear to be affected by
the in vivo hydrodynamics in dog studies.48,49
The independence of happ on GI motility, for small
particles such as jet-milled material, imply that
the in vivo variability would be significantly
reduced within subjects and between subjects.
Therefore, reducing particle size not only im-
proves the dissolution rate and absorption frac-
tion for poorly soluble drugs, but also potentially
minimizes the in vivo variability.
However, it should be emphasized here that
establishing in vitro dissolution methodology
reflecting in vivo scenario requires considerations
in many aspects. For example, pH and surfactants
are critical in selecting an appropriate dissolution
medium. Additionally important factors include
the fluid velocity and device geometry, which
combine to determine the dissolution hydrody-
namics. One disparity between dissolution testing
and the in vivo situation is that the paddle speed
remains unchanged during a given dissolution
test. By contrast, the GI tract regularly transi-
tions through migrating motility cycles and fasted
or fed states. Hence, the GI fluid velocity varies
considerably along various regions of small
intestine,50–53 which can lead to large inter- and
intrasubject variations in in vivo happ. To mimic
the wide range of in vivo happ, it may be more08 DOI 10.1002/jps
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conditions during a test, for example, paddle
speed (Type II tester), dip rate (Type III) and flow
rates (Type IV). It is unrealistic to assume that use
of a single USP dissolution setting such as 50 rpm
can reflect the complete hydrodynamics of a full
GI motility cycle. However, a single paddle speed
might be used to represent one certain GI motility-
fluid flow and particle size combination.
Revision of the test apparatus design to better
reflect the geometry of the intestinal tract and its
flow patterns should be considered. One particu-
larly important aspect to consider is the repre-
sentation of oscillating flow, corresponding to the
segmental mixing in the fed state, which is unique
in its effects on in vivo happ. Applying dimensional
principle, the in vivo happ is a function of:
happ/d¼ f(Re, Sc, St), where Re and Sc are defined
as previously, and St is the Strouhal number
describing oscillatory fluid. St number is calcu-
lated as St¼fl/n0, where f is vortex shedding, l is
the characteristic length (hydraulic diameter),
and n0 is the linear velocity of GI fluid.
Potentially, a dimensionless analysis of the
in vitro hydrodynamics and the in vivo GI motility
using the rule of happ/d¼ f(Re, Sc, St) would be
useful in improving accuracy of predicting in vivo
dissolution and absorption of drug products,
enhancing correlation between in vitro dissolution
and in vivo response and developing in vitro
bioequivalence methods.CONCLUSIONS
The diffusional layer thickness happ was deter-
mined through fenofibrate powder dissolution
testing in a USP apparatus II with various
particle sizes and paddle speeds. The dependence
of happ on drug particle size and dissolution
hydrodynamics, reveals that at 100 rpm the happ
is approximate 1.5-fold of the particle radius or a
constant, which occurs below and above a transi-
tional size of 23.7 mm, respectively. Further, the
result at 50 rpm suggests that a diffusional happ
being linearly proportional to square root of
particle diameter is an overall better functional
form. Further, dimensionless analysis supports a
linear correlation of happ/d with particle Re within
specific particle-hydrodynamic regime. However,
the extrapolation of in vitro results to the in vivo
situation requires further investigation due to theDOI 10.1002/jps JOURNAin vivo hydrodynamics varying with various GI
motility phases.ACKNOWLEDGMENTS
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